Quick Facts

FONT-SIZE

Plus

Neg

SHARE

mail

E-MAIL

Adventrx Pharma Announces Deal With Patheon To Manufacture ANX-188 Drug Product

RELATED NEWS

Adventrx Pharmaceuticals To Present At Cowen Conference; Webcast At 4:10 PM ET

Trade ANX now with

6/26/2012 11:52 AM ET

Adventrx Pharmaceuticals Inc. (ANX: Quote) announced that it has entered into a multi-year agreement with Patheon Inc. under which Patheon will formulate, fill and finish ANX-188 drug product for use in clinical trials, including the phase 3 study of ANX-188 that Adventrx plans to initiate this year.

Click here to receive FREE breaking news email alerts for Mast Therapeutics Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Quick Facts

<<Previous 112 Articles

Editors Pick

Fed Minutes Show Some Members Want To Scale Back QE3 This Summer

Some members of the Federal Reserve favor scaling back the central bank's $85 billion a month asset purchase program this summer as long as the economy continues to improve, according the the minutes of the Fed's April 30-May 1 meeting. "A number of participants expressed willingness to adjust the...

Stocks Come Under Pressure Amid Worries About Fed - U.S. Commentary

After moving mostly higher over the course of morning trading on Wednesday, stocks have shown a notable move back to the downside in the afternoon. The major averages have pulled back well off their highs for the session and into negative territory. The major averages have moved roughly sideways in recent trading, lingering near their new lows for the session.

Immigration Reform Bill Clears Senate Judiciary Committee

Comprehensive immigration reform legislation took a step toward approval on Tuesday, as the members of the Senate Judiciary Committee voted to send the bill to the Senate floor. The Senate Judiciary Committee voted 13 to 5 in favor of the bill, with three Republicans joining with the panel's ten Democrats in voting to support the legislation.

FREE Newsletters & Alerts

Breaking News Alerts

Daily Market Briefing

Health

Technology

Biotechnology

signup

Follow RTT

Most Read
Most E-Mailed

FDA Clears Oramed Pharma's IND For ORMD-0801 - Quick Facts

Plains Exploration Declars Special Dividend - Quick Facts

Covidien Nellcor Pulse Oximetry Portfolio Gets 510(k) Clearance For Motion Claim

Genesys To Buy SoundBite Communications For $5.00 Per Share

Pre-market Movers For May 20 (YHOO, WCRX, ACT, WBSN, CHK, PXP, XNPT, PPHM)

G4S Plc Names Ashley Almanza CEO; Eddie Aston Named New COO

Dolphin Capital Announces Sale Of Venus Rock Golf Resort Interest

Novartis Says BOLERO-3 Study On Afinitor Meets Main Goal

GE Capital To Pay $6.5 Bln In Dividends To GE In 2013, Plans Special Dividend

NetApp Profit Tops Estimates; Boosts Buyback; Initiates Dividend

FDA Clears Oramed Pharma's IND For ORMD-0801 - Quick Facts

Invensys To Return About GBP 625 Mln Cash To Shareholders - Quick Facts

EveryWare Global, ROI Acquisition Complete Business Combination

Covidien Nellcor Pulse Oximetry Portfolio Gets 510(k) Clearance For Motion Claim

GE Capital To Pay $6.5 Bln In Dividends To GE In 2013, Plans Special Dividend

Ensco Shareholders Elect 2 Directors, Pass $2 Bln Share Repurchase Authorization

AIG To Invest $92.5 Mln In Rights Offering By China's PICC

G4S Plc Names Ashley Almanza CEO; Eddie Aston Named New COO

Zytronic H1 Pretax Profit Decreases - Quick Facts

Biogen Idec Submits BLA To FDA For Approval Of Plegridy In Multiple Sclerosis

FREE Newsletters, Analysis & Alerts

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.

Email Address